Back to News
Market Impact: 0.2
Cullinan Therapeutics Outlines Q4 Milestones For T Cell Engager Pipeline
Source: Nasdaq
Healthcare & BiotechCorporate Guidance & Outlook
Cullinan Therapeutics outlined planned fourth-quarter 2026 milestones across its immunology and oncology pipeline. Expected clinical updates will cover velinotamig, CLN-978 and CLN-049, creating potential catalysts for CGEM, although no clinical efficacy or financial data were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
CGEM0.35
More News
- Oracle Japan shares surge 7% after record fiscal first quarter, bucking selloff of U.S. parent
- Costco makes progress on a key membership metric. Here's our new price target on the stock
- Akamai secures $11.6B cloud deal with Anthropic for AI workloads
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- Akamai lands $11.6 billion Anthropic deal, shares soar
- OpenAI says agent hacked Australian government website without being told to do so